about
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?The evolution of insulin glargine and its continuing contribution to diabetes careModern basal insulin analogs: An incomplete storyClinical utility of insulin and insulin analogs.Insulin excites anorexigenic proopiomelanocortin neurons via activation of canonical transient receptor potential channels.Nanoparticle-allergen complexes for allergen immunotherapy.Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.Identifying knowledge deficits of food insecure patients with diabetes.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Subconjunctivally Implanted Hydrogels for Sustained Insulin Release to Reduce Retinal Cell Apoptosis in Diabetic RatsLooking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.Future of newer basal insulinNew insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).The past, present, and future of basal insulins.Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesCross-inhibition of pathogenic agents and the host proteins they exploit.Development of novel HDL-mimicking α-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution.[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.Integration of cell-free protein synthesis and purification in one microfluidic chip for on-demand production of recombinant proteinImproved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
P2860
Q24624156-31592CF4-2218-481F-82E1-86D4D87124A5Q26999454-D4E8D38A-1707-4686-B24D-7241F1BA2060Q27015047-581E4C5F-2E8F-4EDF-B614-1431EB85ED03Q30429358-608636AA-4656-4424-8953-61DAB4B7462CQ30588792-9DDD37CC-B020-4E7E-BFC8-A7C853BDDBC6Q33834985-AE72612C-48A3-4400-8434-F64DADD8D7F7Q34085107-22D91725-39EF-46D2-A60F-10AA1AE17FD1Q35162886-D2EB9C5E-73F7-4362-AC74-3EC140741A72Q35671873-C838BD51-01F8-46C5-ACA6-AE96B09F625FQ36380233-73B9A2C2-DDC5-413B-A308-1761A49FE537Q36694319-FF08970F-461F-46E8-B4D5-ECD615993F9BQ36930701-78018776-F6E1-4878-83F6-4019E2F868BAQ37343847-5C798BBD-5EED-45CC-8442-7A08D95D3398Q38618376-E70CFEFD-733F-4C1A-B03A-EFAEFF680A86Q38672852-BF1C2928-D6B0-4F9A-8986-239CDED707ECQ38824504-8BECAD10-9394-406B-9233-FFE8A8EC10C7Q41323155-7985D627-3693-420D-8BEC-75CB2F2A0090Q42849111-496BF458-7F55-4F67-B02D-204AC6490E7FQ52836101-8787B79A-8E9C-447F-8ACB-C54E9D40194FQ55383414-ACDD6A90-558A-4165-A436-EB1EAC3EE872Q57074978-7FBA6D74-63F4-4418-9005-707BC0219C56Q57298454-67F39986-C3EE-4B85-8720-F61B2D638F04
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Insulin preparations with prolonged effect.
@ast
Insulin preparations with prolonged effect.
@en
Insulin preparations with prolonged effect.
@nl
type
label
Insulin preparations with prolonged effect.
@ast
Insulin preparations with prolonged effect.
@en
Insulin preparations with prolonged effect.
@nl
prefLabel
Insulin preparations with prolonged effect.
@ast
Insulin preparations with prolonged effect.
@en
Insulin preparations with prolonged effect.
@nl
P356
P1476
Insulin preparations with prolonged effect.
@en
P2093
David R Owens
P356
10.1089/DIA.2011.0068
P478
13 Suppl 1
P577
2011-06-01T00:00:00Z